title: Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
abstract: BACKGROUND
  Telavancin is a novel lipoglycopeptide derivative of vancomycin that has activity against Gram-positive aerobic and anerobic bacteria, for the treatment of serious infections, including complicated skin and skin structure infections (cSSSI) and pneumonia.
  
  
  METHODS
  This article was compiled through searches on telavancin up to December 2015 in the PubMed and the clinicaltrials.gov databases; the FDA and European Medicine Agency (EMA) websites. In our review, particular attention was paid to those articles that reviewed the pharmacokinetic characteristics of the drug and animal models of infection. We also searched for evidence of the efficacy of telavancin as demonstrated in clinical trials, safety and tolerability data and have compiled a summary of clinical trials on telavancin in pneumonia.
  
  
  CONCLUSIONS
  Telavancin is approved in Europe and the USA for the treatment of nosocomial pneumonia caused by methicillin resistant Staphylococcus aureus when other alternatives are not suitable.
authors.affiliation: a 6th Respiratory Department , Sotiria Hospital , Athens , Greece.
authors.forename: Liapikou
authors.initials: L
authors.lastname: Adamantia
authors.affiliation: b Department of Pneumology , Hospital Clinic of Barcelona , Barcelona , Spain.
authors.forename: Torres
authors.initials: T
authors.lastname: Antoni
mesh_terms: D000617:Aminoglycosides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D004195:Disease Models, Animal; D006094:Gram-Positive Bacteria / Q000187:drug effects; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy / Q000382:microbiology
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; C487637:telavancin
keywords: Methicillin-resistant Staphylococcus aureus; pneumonia; telavancin; vancomycin